DNTH insider buying – Dianthus Therapeutics, Inc. /DE/
5 insider purchases since 2016 worth $1.5M by 3 different insiders. Last 12 months: 0 purchases, $0. Most recent filing: 2023-10-03.
Mid company Public float $599M (latest 10-K, SEC).
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| Kiselak Tomas Director | $1.1M 3× · 84,254 sh | 2023-09-12 2023-09-26 | – | 2,700,691 shares as of 2024-10-01 | Holds - never sold |
| Harwin Peter Evan Director | $336,252 1× · 24,670 sh | 2023-09-29 2023-09-29 | – | 1,928,503 shares as of 2023-10-03 | Holds - never sold |
| Randhawa Simrat Officer | $52,800 1× · 4,000 sh | 2023-09-21 2023-09-21 | 4× · $15.0M last 2026-09-01 | 4,000 shares as of 2026-09-03 | Sold part |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 18 | $74.1M |
| 2025 | 0 | – | – | 3 | $9.0M |
| 2023 | 5 | $1.5M | 3 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2023-10-03 | Harwin Peter Evan | Director | 24,670 | $13.63 | $336,252 | +1.3% | SEC |
| 2023-09-28 | Kiselak Tomas | Director | 30,000 | $13.15 | $394,500 | +1.6% | SEC |
| 2023-09-25 | Randhawa Simrat | Officer | 4,000 | $13.20 | $52,800 | SEC | |
| 2023-09-21 | Kiselak Tomas | Director | 30,000 | $13.20 | $396,000 | +1.6% | SEC |
| 2023-09-13 | Kiselak Tomas | Director | 24,254 | $11.20 | $271,680 | +1.3% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-11-12 | Savitz Ryan | EVP, CFO & CBO | -124,042 | $90.52 | $11.2M | Pre-planned (10b5-1) | SEC |
| 2026-09-18 | CARR EDWARD | Officer | 20,000 | $101.38 | $2.0M | Sale | SEC |
| 2026-09-03 | Randhawa Simrat | Officer | 23,124 | $106.41 | $2.5M | Sale | SEC |
| 2026-08-19 | Read Simon | Director | 2,778 | $117.55 | $326,554 | Sale | SEC |
| 2026-08-11 | Read Simon | Director | 2,777 | $109.55 | $304,232 | Sale | SEC |
| 2026-08-11 | McGeorge Anne | Director | 7,750 | $109.01 | $844,822 | Sale | SEC |
| 2026-08-11 | Veness Adam M | Officer | 20,000 | $110.44 | $2.2M | Sale | SEC |
| 2026-08-07 | Garcia Marino | CEO | 166,000 | $108.11 | $17.9M | Sale | SEC |
| 2026-07-13 | Savitz Ryan | CFO | 31,249 | $101.03 | $3.2M | Sale | SEC |
| 2026-06-18 | Veness Adam M | Officer | 30,000 | $80.80 | $2.4M | Sale | SEC |
| 2026-06-02 | Randhawa Simrat | Officer | 26,530 | $90.62 | $2.4M | Sale | SEC |
| 2026-05-11 | Soteropoulos Paula | Director | 599 | $85.47 | $51,197 | Sale | SEC |
| 2026-04-10 | Savitz Ryan | CFO | 8,224 | $89.84 | $738,844 | Sale | SEC |
| 2026-04-01 | Savitz Ryan | CFO | 114,367 | $83.00 | $9.5M | Sale | SEC |
| 2026-03-26 | Soteropoulos Paula | Director | 27,594 | $78.05 | $2.2M | Sale | SEC |
Showing the latest 15 of 21 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free